Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-01-27
1995-06-27
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 19, 5142305, 544 92, 530331, A61K 3805, A61K 3806, A61K 31535, C07D26524
Patent
active
054280214
ABSTRACT:
Novel therapeutic agents useful as inhibitors of HLE are provided. The compounds have the structural formula (I) ##STR1## wherein R.sup.1 through R.sup.9, m, n and p are as defined herein. Methods of using the compounds of formula (I) to inhibit serine proteases and to treat physiological conditions and disease states associated with elevated HLE levels are also provided, as are pharmaceutical compositions containing the compounds.
REFERENCES:
patent: 4980287 (1990-12-01), Kokubo et al.
Krantz et al. (1990) J. Med. Chem. 33:464-479.
H. Carp et al., Potential mechanism of emphysema: .alpha..sub.1 -Proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity, Proc. Natl. Acad. Sci. 770:2041-2045 (1982).
L. J. Copp, et al. , Kinetics and mechanism of human leukocyte elastase inactivation by ynenol lactones Biochemistry 26:169-178 (1987).
P. D. Edwards, Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl .alpha.-Ketobenzoxazoles, and the X-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-Benzoxazole, J. Am. Chem. Soc. 114:1854-1863 (1992).
L. Eskerot et al., Interactions of granulocyte proteases with inhibitors in rheumatoid arthritis, Adv. Exp. Med. Biol. 167:335-344 (1984).
P. E. Finke, et al., Inhibition of human leukocyte elastase. 4. Selection of a substituted cephalosporin (L-658,758) as a topical aerosol, J. Med. Chem. 35:3731-3744 (1992).
J. W. Harper, et al., Reaction of serine proteases with substituted 3-Alkoxy-4-chloroisocoumarins and 3-Alkoxy-7-amino-4-chloroisocoumarins: New reactive mechanism-based inhibitors, Biochemistry 24:7200-7213 (1985).
J. W. Harper, et al., Reaction of serine proteases with substituted isocoumarins: Discovery of 3,4-Dichloroisocoumarin, a new general mechanism based serine protease inhibitor, Biochemistry 24:1831-1841 (1985).
C. H. Hassal et al., A new class of inhibitors of human leucocyte elastase, FEBS Lett. 183:201-205 (1985).
M. A. Hernandez, et al., Effect of the 7-Amino substituent on the inhibitory potency of mechanism-based isocoumarin inhibitors for porcine pancreatic and human neutrophil elastases: A 1.85-.ANG.-X-ray structure of the complex between porcine pancreatic elastase and 7-[(N-Tosylphenylalanyl)amino]-4-chloro-3-methoxyisocoumarin, J. Med. Chem. 35:1121-1129 (1992).
A. H. Jackson et al., Sputum sol-phase proteins and elastase activity in patients with systic fibrosis, J. Respir. Dis. 65:114-124 (1984).
A. Janoff, Elastase in tissue injury, Annu. Rev. Med. 36:207-216 (1985).
A. Janoff, Elastases and emphysema; Current assessment of the protease-antiprotease hypothesis, Am. Rev. Respir. Dis. 132:417-433 (1985).
D. H. Kinder et al., Acylamino boronic acids and difluoroborane analogues of amino acids: Potent inhibitors of chymotrypsin and elastase, J. Med. Chem. 28:1917-1925 (1985).
A. Krantz et al., Design and synthesis of 4H-3,1-Benzoxazin-4-ones as potent alternate substrate inhibitors of human leukocyte elastase, J. Med. Chem. 33:464-479 (1990).
C.-B. Laurell et al., The electrophoretic .alpha..sub.1 -Antitrypsin deficiency, Scand. J. Clin. Lab. Invest. 15:132-140 (1963).
S. Mehdi et al., The inhibition of human neutrophil elastase and cathepsin G by peptidyl 1,2-Dicarbonyl derivatives, Biochem. Biophys. Res. Commun. 166:201-205 (1990).
T. A. Merritt et al., Elastase and .alpha..sub.1 -Proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome, J. Clin. Invest. 72:656-666 (1983).
H. P. Schnebli, Recombinant elastase inhibitors for therapy, Ann. N.Y. Acad. Sci. 624:212-218 (1991).
S. K. Shah, et al., Orally active .beta.-Lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-Diethyl-2-azetidinones, J. Med. Chem. 35:3745-3754 (1992).
J. W. Skiles et al., Inhibition of human leukocyte elastase (HLE) by N-substituted peptidyl trifluoromethyl ketones, J. Med. Chem. 35:641-662 (1992).
R. A. Stockley et al., Proteinases in chronic lung infection Ann. N.Y. Acad. Sci. 624:257-266 (1991).
J. C. Taylor et al., Pulmonary emphysema and proteolysis, New York: Academic Press, (1987).
R. A. Wildonger et al., The in vitro and in vivo inhibition of human leukocyte elastase by .alpha.,.alpha.-difluoro-.beta.-ketoamides, in Eleventh American Symposium Abstracts, poster 87, presented at the University of California, San Diego, Jul. 9-14, 1989.
Hiebert Charles K.
Laibelman Alan
Ryan Kenneth J.
Grumbling Matthew V.
Reed Dianne E.
Shah Mukund J.
SRI - International
LandOfFree
Human leukocyte elastase (HLE) inhibitors, and related pharmaceu does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human leukocyte elastase (HLE) inhibitors, and related pharmaceu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human leukocyte elastase (HLE) inhibitors, and related pharmaceu will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-287565